CytoMed和SunAct在印度参加癌症治疗细胞的测试,尽管CytoMed的库存下降。 CytoMed and SunAct join to test cancer-treatment cells in India, despite CytoMed's stock dropping.

以新加坡为基地的生物制药公司CytoMed治疗技术公司与印度太阳行动癌症研究所合作,研究CytoMed的异族性伽马丁酸T细胞在治疗包括固态肿瘤在内的各种癌症方面的有效性和安全性。 CytoMed Therapeutics, a Singapore-based biopharmaceutical company, has teamed up with India's SunAct Cancer Institute to research the effectiveness and safety of CytoMed's allogeneic gamma delta T cells in treating various cancers, including solid tumors. 这一合作包括在印度进行第二阶段临床试验,两家公司是联合赞助者。 This collaboration includes a Phase 2 clinical trial in India, with both companies as joint sponsors. 尽管合作充满希望,但CytoMed的股份在宣布后下降了7%。 Despite the promising partnership, CytoMed's shares dropped by 7% following the announcement.